Active Implants develops orthopedic implant solutions, principally the investigational NUsurface Meniscus Implant for patients with persistent knee pain after medial meniscus surgery. The NUsurface implant is made from medical-grade polymer, does not require fixation to bone or soft tissues, and is designed to mimic the natural meniscus and redistribute loads across the knee joint. The device has been used in Europe under CE Mark since 2008 and in Israel since 2011; clinical trials are underway in the U.S., Europe and Israel to verify safety and effectiveness. The company is running the SUN and VENUS clinical trials and says recruitment is going extremely well, with expected completion of enrollment by the end of the year. Active Implants cites an addressable U.S. population of more than 130,000 appropriate meniscectomy patients per year and notes that 700,000 to over 1 million arthroscopic partial meniscectomies are performed annually in the U.S., with annual direct medical costs estimated at $4 billion. The company is privately held, headquartered in Memphis, Tennessee, with European offices in Driebergen and R&D facilities in Netanya, Israel; recent financing proceeds will be used to continue its research and clinical development programs. Active Implants LLC develops the NUsurface® Meniscus Implant, a cushion-bearing composite polymer device intended to treat knee patients with osteoarthritis related to prior meniscectomy or meniscus insufficiency. The implant is designed for patients too old for meniscus repair and too young for total knee replacement, aiming to fill a treatment gap between non-operative care and knee replacement. Clinical studies outside the U.S. have demonstrated superiority over current standard-of-care treatments, and the company is conducting a prospective controlled Multi-Center Trial in Europe and Israel that is enrolling patients. Active Implants works with leading knee sports medicine surgeons, including Peter Verdonk, M.D., Ph.D., and cites positive results observed to date. The company estimates the potential worldwide market for the NUsurface product to be in excess of $2.0 billion annually. Active Implants is privately held with headquarters in Memphis, TN and additional offices in Driebergen, The Netherlands and Netanya, Israel. Active Implants Corporation develops a pliable orthopaedic implant, the NUsurface® Meniscus Implant, intended to relieve knee pain and restore function by redistributing load similar to a healthy meniscus. The implant is placed by orthopaedic surgeons using a mini-open procedure in conjunction with routine arthroscopy. The company received $10m in convertible debt from existing investors and intends to use the funds to complete enrollment and follow up of the clinical study of the NUsurface implant. In conjunction with the transaction, long-time board member Henry Klyce assumed the role of CEO. Active Implants was formed in 2004 and maintains research facilities in Netanya, Israel.

Total raised

$29M

Funding rounds

3

Latest round

Series D

Latest activity

Mar 2017